ClinicalTrials.gg
CompletedNCT05309109EMCOPEWUpdated Oct 29, 2026Results posted

Effect of Medium Cut-Off Hemodialysis on Protein Energy Wasting: The EMCOPEW Study

An interventional study of Hemodialysis sessions in End Stage Renal Disease (ESRD), sponsored by Poitiers University Hospital. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Other

How we know

Updated Oct 29, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.

Enrollment
57th of 105
65 · median 70
Started
2022
with 6 others
No phase
55 of 145
10 open now
Registered
117th of 145
by date

Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 57th largest by enrollment of the 105 interventional ones that give a count, is one of 7 that started in 2022, is one of 55 with no phase, and was the 117th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Kidney Failure, Chronic with a site in France, or all of them as a file.
02

Study summary

In patients on maintenance hemodialysis (HD), protein energy wasting (PEW) defined as loss of muscle mass and fuel reserves of the body is frequent and associated with severe morbidity and mortality. Several factors, including inflammation, oxidative stress, metabolic disorders, loss of nutrients, diabetes, retention of middle molecule uremic toxins and dialysis procedure contribute to PEW. It has been previously reported that intensive HD treatments such as short daily and nocturnal HD may improve nutritional parameters. Moreover, post-dilution Online hemodiafiltration (OL-HDF) may also improve PEW by preserving lean body mass evaluated by bioimpedance analysis (BIA) probably through decreased inflammation, stimulation of appetite and better removal of uremic toxins. The recently developed medium cut-off dialyzer (MCO) in HD has demonstrated efficient depuration of middle uremic toxins as compared to high flux HD (HF-HD), similar to that of OL-HDF. Both MCO-HD and OL-HDF may exert beneficial effects on PEW, since they increase removal of higher weight middle molecules, which mostly encompass proteins related to inflammation and PEW in the uremic milieu

Read the detailed description

In a previous randomized study, we found, that after 3 months, MCO-HD was associated with higher middle molecules removal and significant decrease in beta2-microglobulin, oxidized low-density lipoprotein, kappa and lambda free light chain pre-dialysis levels, without change in other inflammatory and oxidative stress biomarkers. In addition, compared to HF-HD, a modulation of inflammation has been demonstrated with MCO-HD in another randomized trial. After 3 months, MCO-HD was shown to downregulate the expression of the pro-inflammatory IL-6 and tumor necrosis factor (TNF) mRNA in peripheral leucocytes. Moreover, higher removal and decrease in TNF alpha level with concurrent reduced resistance to erythropoiesis stimulating agents (ESA) has been also reported with MCO-HD. However, the long-term effects of MCO-HD on inflammatory, uremic toxins and malnutrition biomarkers remain to be established.

To test the hypothesis that MCO-HD may positively affect body composition and nutritional status in HD patients we performed a 12-month single center retrospective pilot study. Compared to HF-HD, MCO-HD resulted in an improved variation rate of serum pre-dialysis creatinine level, lean tissue, skeletal muscle mass and index assessed by BIA, which are presumably good surrogate markers of PEW.

The aim of the present prospective, controlled randomized study is to evaluate the effect of MCO-HD on PEW, compared to standard HF-HD in chronic hemodialysis patients.

03

Conditions studied

  • End Stage Renal Disease (ESRD)

Keywords

  • hemodialysis
  • protein energy wasting
  • medium cut-off dialyzer
  • lean mass
  • bioimpedance
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients able to give signed
  • Age ≥ 18 years
  • Patients established on HF-HD trice weekly four hour-sessions for at least 3 months.
  • Patients able to walk
  • ≥ 20 and \< 40 Kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled medical condition, psychiatric disorder or biological abnormality that might interfere with subject's participation or ability to sign an .
  • Implanted pace maker or cardioverter defibrillator
  • Pregnant or breast-feeding women
  • Active malignant disease, chronic inflammatory disease or other critical illnesses that may interfere with inflammatory parameters. Baseline C-reactive protein > 35 mg/l.
  • Amputated limbs
  • Prescription of oral or intra venous nutrition supplements
  • Significant residual kidney function as defined by an urine output > 500 mL
  • Patients allergic to polyethersulfone membranes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    MCO-HD group

    Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg)

    Other: Hemodialysis sessions

  • Experimental
    HF-HD group

    Hemodialysis sessions using the Elisio 21H™ (Nipro Europe, Zaventen Belgium; surface area 2.1 m², ultrafiltration coefficient: 82 ml/h/mmHg)

    Other: Hemodialysis sessions

Interventions

  • OtherHemodialysis sessions

    Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.

06

What researchers measure

Primary outcomes

  1. The Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study.

    The difference between the lean tissue mass measured at 12 months and the lean tissue mass measured at baseline.

    Time frame: 12 months

07

Results

Posted Oct 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneMCO-HD GroupHF-HD Group
Started3232
Completed2423
Not completed89

Outcome measures

PrimaryThe Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study.

The difference between the lean tissue mass measured at 12 months and the lean tissue mass measured at baseline.

Time frame:
12 months
Reported as:
Mean · kg
The Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study.
kgMCO-HD GroupHF-HD Group
The Change From Baseline to the End of the Study in Lean Tissue Mass Measured Using Bioimpedance Analysis Through the Study.0.57 (-3.51 to 4.65)0.32 (-4.02 to 4.67)

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCO-HD Group2/32 (6.3%)0/32 (0%)1/32 (3.1%)
HF-HD Group3/32 (9.4%)0/32 (0%)0/32 (0%)
Most frequent other events
Most frequent other events
EventMCO-HD GroupHF-HD Group
hypotensive eventVascular disorders1/320/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)MCO-HD GroupHF-HD GroupTotal
Median70.5 (65.5 to 74)70.0 (62.0 to 76.0)70.0 (64.0 to 75.0)
Sex: Female, Male
Sex: Female, Male(Participants)MCO-HD GroupHF-HD GroupTotal
Female71017
Male171330
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)MCO-HD GroupHF-HD GroupTotal
Count of participants——0
lean tissue mass at baseline
lean tissue mass at baseline(kg)MCO-HD GroupHF-HD GroupTotal
Mean44.7 ± 12.544.1 ± 11.644.4 ± 12.0
08

Study locations

2 sites
  • CHU de Poitiers
    Poitiers, 86000, France
  • AURA Poitou-Charentes
    Saint-Benoît, 86281, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Mar 2025, 30 months.

Results were first posted in Oct 2026, 1 year 7 months after primary completion.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 30 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 4, 2022
StartActual
Sep 26, 2022
Primary completionActual
Mar 27, 2025
CompletionActual
Mar 27, 2025
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedPatients allergic to polyethersulfone membranes
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe change from baselineChange From Baseline to the endEnd of the studyStudy in lean tissue mass measured usingLean Tissue Mass Measured Using Bioimpedance analysis throughAnalysis Through the studyStudy.Time frame: 12 months
Oct 29, 2026
Documents
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedPatients allergic to polyethersulfone membranes
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe change from baselineChange From Baseline to the endEnd of the studyStudy in lean tissue mass measured usingLean Tissue Mass Measured Using Bioimpedance analysis throughAnalysis Through the studyStudy.Time frame: 12 months
    + 4 other changes: index terms, oversight details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05309109
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
Sep 26, 2022
Primary completion
Mar 27, 2025
Completion
Mar 27, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion